公开(公告)号：US10532053B2

公开(公告)日：2020-01-14

申请号：US15558370

申请日：2016-03-17

Applicant: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

Inventor： Lijuan Chen ,  Chaofeng Long ,  Xiaoxin Chen ,  Zhuowei Liu ,  Haoyu Ye ,  Chenshi Xie

IPC: C07D239/94 ,  C07D401/12 ,  C07D403/12 ,  A61K31/517 ,  A61P35/00

Abstract: A compound represented by Formula I or pharmaceutically acceptable salt thereof. The present invention relates to a 4-arylamino quinazoline hydroxamic acid compound having a histone deacetylase inhibitory activity, preparation method of the compound, pharmaceutical composition comprising the compound, and use of the compound and the pharmaceutical composition in the preparation of a histone deacetylase inhibitor medicine. The present invention aims at acquiring, via a medicine design and a synthetic technology, a series of selective histone deacetylase inhibitors having good hypotype selectivity and favorable pharmacokinetic characteristics based on optimization of an enzyme surface recognition region and connection region of 4-arylamino quinazoline, thus reducing an effect on normal tissues or cells while improving an antineoplastic activity of the normal tissues or cells. In Formula I, the variables are as described herein.

公开(公告)号：US09938292B2

公开(公告)日：2018-04-10

申请号：US15128064

申请日：2015-03-16

Applicant: GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD

Inventor： Hao Wu ,  Chaofeng Long ,  Jun Lin ,  Xiaoxin Chen ,  Yunhui Li ,  Zhuowei Liu ,  Changqing Wei ,  Lijuan Chen ,  Shuhui Chen

IPC: C07D413/10 ,  C07D413/14 ,  C07D403/10 ,  C07D403/14 ,  C07D498/04 ,  C07D401/10 ,  C07D491/08 ,  C07D487/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D487/08 ,  C07D487/10 ,  C07D471/10

CPC classification number: C07D498/04 ,  C07D215/38 ,  C07D401/04 ,  C07D401/10 ,  C07D401/12 ,  C07D401/14 ,  C07D405/12 ,  C07D413/10 ,  C07D413/12 ,  C07D413/14 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/08 ,  C07D471/10 ,  C07D487/04 ,  C07D487/08 ,  C07D487/10 ,  C07D491/08 ,  C07D498/08

Abstract: Disclosed are quinoline derivatives as hedgehog pathway inhibitors, especially as SMO inhibitors. Compounds of the present invention can be used in treating diseases relating to hedgehog pathway including cancer.